Opus Genetics (IRD) vs. Its Rivals Head-To-Head Survey

Opus Genetics (NASDAQ:IRD) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Opus Genetics to related businesses based on the strength of its dividends, risk, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Insider & Institutional Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Opus Genetics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Opus Genetics’ peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Opus Genetics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Opus Genetics Competitors	-12,359.35%	-203.09%	-30.93%

Earnings & Valuation

This table compares Opus Genetics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Opus Genetics	$14.20 million	-$49.59 million	-2.97
Opus Genetics Competitors	$735.05 million	$13.62 million	-14.86

Opus Genetics’ peers have higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations for Opus Genetics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	16	1	2.89
Opus Genetics Competitors	9800	15084	45398	1579	2.54

Opus Genetics presently has a consensus price target of $12.71, suggesting a potential upside of 217.06%. As a group, “Biotechnology” companies have a potential upside of 104.13%. Given Opus Genetics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Opus Genetics is more favorable than its peers.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.